Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor β - Integrin α3β1 interaction

Clinical and Experimental Metastasis

Volumn 16, Issue 6, 1998, Pages 529-539

  Klominek, Julius ^a   Baskin, Berivan ^b   Hauzenberger, Dan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chemotaxis; Integrins; Malignant mesothelioma; PDGF; PDGF receptors

Indexed keywords

CHEMOATTRACTANT; INTEGRIN; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; FLOW CYTOMETRY; MALIGNANT MESOTHELIOMA; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING;

CHEMOTACTIC FACTORS; CHEMOTAXIS; HUMANS; INTEGRIN ALPHA3BETA1; INTEGRINS; MESOTHELIOMA; NEOPLASM PROTEINS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0032417650     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006542301794     Document Type: Article

References (62)

1. Ross R, Raines EW and Bowen-Pope DF, 1986, The biology of platelet-derived growth factor. Cell, 46, 155-9.
2. Raines EW and Ross R, 1993, Platelet-derived growth factor in vivo. In: Westermark B and Sorg C, eds. Biology of Platelet-derived Growth Factor. Basel: Karger, pp. 74-114.
3. Heldin C-H and Westermark B, 1989, Platelet-derived growth factor: three isoforms and two receptor types. Trends Genet, 4, 108-11.
4. Heldin C-H and Westermark B, 1990, Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regulat, 1, 555-66.
5. Williams LT, 1989, Signal transduction by the platelet-derived growth factor receptor. Science, 243, 1564-70.
6. Kazlauskas A and Cooper JA, 1989, Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. Cell, 58, 1121-33.
7. Escobedo JA and Williams LT, 1988, A PDGF receptor domain essential for mitogenesis but not for many other responses to PDGF. Nature, 335, 85-7.
8. Heldin C-H, Westermark B and Wasteson Å, 1980, Chemical and biological properties of a growth factor from human cultured osteosarcoma cells: resemblance with platelet-derived growth factor. J Cell Physiol, 105, 235-46.
9. Rozengurt E, Sinnett-Smith J and Taylor-Papadimitriou J, 1985, Production of PDGF-like growth factor by breast cancer cell lines. Int J Cancer, 36, 247-52.
10. Heldin C-H, Johnsson A, Wennergren S, et al. 1986, A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A chains. Nature, 319, 511-14.
11. Hammacher A, Nistér M, Westermark B and Heldin C-H, 1988, A human glioma cell line secretes three structurally and functionally different dimeric forms of platelet-derived growth factor. Eur J Biochem, 176, 179-86.
12. Seppa H, Grotendorst G, Seppa S, et al. 1982, Platelet-derived growth factor is chemotactic for fibroblasts. J Cell Biol, 92, 584-8.
13. Forsberg K, Valyi-Nagy I, Heldin C-H and Westermark B, 1993, Platelet-derived growth factor (PDGF) in oncogenesis: development of vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA, 90, 393-7.
14. Cunningham RS, 1926, The physiology of the serous membranes. Physiol Rev, 6, 242-77.
15. Donna A and Betta PG, 1981, Mesodermomas: a new embryological approach to primary tumours of coelomic surfaces. Histopathol, 5, 31-44.
16. Antman KH, 1981, Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol, 8, 313-20.
17. Suzuki Y, 1980, Pathology of human malignant mesothelioma. Semin Oncol, 8, 268-82.
18. Boutin C, Rey F and Viallat JR, 1995, Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest, 108, 754-8.
19. Boutin C, Rey F, Gouvernet J, et al. 1993, Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer, 72, 394-404.
20. Boutin C and Rey F, 1993, Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis, Cancer, 72, 389-93.
21. Goodman SL, Vollmers PH and Birchmeier W, 1985, Control of cell locomotion: perturbation with an antibody directed against specific glycoproteins. Cell, 41, 1029-38.
22. Liotta LA, Steeg P and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-36.
23. Liotta LA, Mandler R, Murano G, et al. 1986, Tumor cell autocrine motility factor. Proc Natl Acad Sci USA, 83, 3302-6.
24. Stoker M and Gherardi E, 1991, Regulation of cell movement: the motogenic cytokines. Biochem Biophys Acta, 1072, 81-102.
25. Stracke ML, Kohn EC, Aznavoorian SA, et al. 1988, Insulin-like growth factors stimulate chemotaxis in human melanoma cells. Biochem Biophys Res Commun, 153, 1076-83.
26. Weidner MJ, Behrens J, Vandekerckhove J and Birchmeier W, 1990, Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol, 111, 2097-108.
27. Matsui T, Sano K, Tsukamoto T, et al. 1993, Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling. J Clin Invest, 92, 1153-60.
28. Sekido Y, Takahashi T, Ueda R, et al. 1993, Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res, 53, 1709-14.
29. Klominek J, Liu Z, Baskin B and Hauzenberger D, 1998, Human hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer 76, 240-249, 1998.
30. Siri A, Carnemolla B, Raffanti S, et al. 1984, Fibronectin concentrations in pleural effusions of patients with malignant and non-malignant diseases. Cancer Lett, 22, 1-9.
31. Kenworthy P, Dowrick P, Baillie-Johnson H, et al. 1992, The presence of scatter factor in patients with metastatic spread to the pleura. Br J Cancer, 66, 243-7.
32. Gerwin BI, Lechner JF, Reddel RR, et al. 1987, Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res, 47, 6180-4.
33. Versnel MA, Claesson-Welsh L, Hammacher A, et al. 1991, Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene, 6, 2005-11.
34. Schmitter D, Lauber B, Fagg B and Stahel RA, 1992, Hematopoetic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer, 51, 296-301.
35. Lauber B, Leuthold M, Schmitter D, et al. 1992, An autocrine mitogenic activity produced by pleural mesothelioma cell line. Int J Cancer, 50, 943-50.
36. Pelin-Enlund K, Husgafvel-Pursiainen K, Tammilehto L, et al. 1990, Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogen, 11, 673-81.
37. Klominek J, Robért K-H, Hjerpe A, et al. 1989, Serum-dependent growth patterns of two, newly established human mesothelioma cell lines. Cancer Res, 49, 6118-22.
38. Chomczynski P and Sacchi N, 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem, 162, 156-9.
39. Islam KB, Baskin B, Nilsson L, et al. 1994, Molecular analysis of IgA deficiency. Evidence for impaired switching to IgA. J Immunol, 152, 1442-52.
40. Boyden S, 1961, The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med, 115, 453-66.
41. Klominek J, Sundqvist K-G and Robért K-H, 1991, Nucleokinesis: distinct pattern of cell translocation in response to an autocrine motility factor-like substance or fibronectin. Proc Natl Acad Sci USA, 88, 3902-6.
42. Zigmond SH and Hirsch JG, 1973, Leukocyte locomotion and chemotaxis: new methods for evaluation and demonstration of a cell derived chemotactic factor. J Exp Med, 137, 387-410.
43. Grotendorst GR, Seppä HEJ, Kleinman HK and Martin GR, 1981, Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. Proc Natl Acad Sci USA, 78, 3669-72.
44. Westermark B, Siegbahn A, Heldin CH and Claesson-Welsh L, 1990, B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase. Proc Natl Acad Sci USA, 87, 128-32.
45. Akiyama T and Ogawara H, 1991, Use and specificity of genistein as inhibitor of protein tyrosine kinases. Meth Enzymol, 201, 362-70.
46. Klominek J, Robért K-H and Sundqvist K-G, 1993, Chemotaxis and haptotaxis of human malignant mesothelioma cells. Effects of fibronectin, laminin, type IV collagen and an autocrine motility factor-like substance. Cancer Res, 53, 4376-82.
47. Klominek J, Sumitran S and Hauzenberger D, 1997, Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of β1 integrins. Int J Cancer, 72, 1034-44.
48. Hynes R, 1992, Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69, 11-25.
49. Ahlen K and Rubin K, 1994, Platelet-derived growth factor-BB stimulates synthesis of the integrin alpha 2-subunit in human diploid fibroblasts. Exp Cell Res, 215, 347-53.
50. Fujii K, Dousaka-Nakajima N and Imamura S, 1995, Epidermal growth factor enhancement of HSC-1 human cutaneous squamous carcinoma cell adhesion and migration on type I collagen involves selective up-regulation of alpha 2 beta 1 integrin expression. Exp Cell Res, 216, 261-72.
51. Nistér M, Claesson-Welsh L, Eriksson A, et al. 1991, Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem, 266, 16755-63.
52. Westermark B and Heldin C-H, 1991, Platelet-derived growth factor in autocrine transformation. Cancer Res, 51, 5087-92.
53. Tzanakakis GN, Karamanos NK, Klominek J and Hjerpe A, 1995, Glycosaminoglycans from two human malignant mesothelioma cell lines: determination, distribution, and effect of platelet-derived growth factor on their synthesis. Biochem Cell Biol, 73, 59-66.
54. Pass HI, Stevens EJ, Oie H, et al. 1995, Characteristics of nine newly derived mesothelioma cell lines. Ann Thoracic Surg, 59, 835-44.
55. Langerak AW, De Laat PA and Van Der Linden-Van Beurden CA, et al. 1996, Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol, 178, 151-60.
56. Ullrich A and Schlessinger J, 1990, Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203-12.
57. Stracke ML, Krutzsch HC, Unsworth EJ, et al. 1992, Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulatina protein. J Biol Chem, 267, 2524-9.
58. Aznavoorian S, Stracke ML, Krutzsch H, et al. 1990, Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol, 110, 1427-38.
59. Kohn EC, Francis EA, Liotta LA and Schiffmann E, 1990, Heterogeneity of the motility responses in malignant tumor cells: a biological basis for the diversity and homing of metastatic cells. Int J Cancer, 46, 287-92.
60. Guirguis R, Margulies I, Taraboletti G, et al. 1987, Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration. Nature, 329, 261-3.
61. Wang JM, Taraboletti G, Matsushima K, et al. 1990, Induction of haptotactic migration of melanoma cells by neutrofil activating protein/interleukin-8. Biochem Biophys Res Commun, 169, 165-70.
62. Silletti S, Watanabe H, Hogan V, Nabi IR and Raz A, 1991, Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res, 51, 3507-11.